Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma.
Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma.
复制标题
脾红髓低度B细胞淋巴瘤的临床病理分析。
DOI：
10.1111/pin.12909
复制
发表时间：
2020
影响因子：
2.2
通讯作者：
Ohshima K.
中科院分区：
文献类型：
--
作者：
Suzuki T;Miyoshi H;Shimono J;Kawamoto K;Arakawa F;Furuta T;Yamada K;Yanagida E;Takeuchi M;Seto M;Sone H;Takizawa J;Ohshima K.
原发性脾红髓低度 B 细胞淋巴瘤包括毛细胞白血病 (HCL) 和无法分类的脾 B 细胞淋巴瘤/白血病 (SPLL-U)。 SPLL-U 是一种罕见疾病，包括毛细胞白血病变异型 (HCL-v)、脾弥漫性红髓小 B 细胞淋巴瘤 (SDRPL) 和其他被称为狭义 SPLL-U (SPLL-U-NS) 的类型。值得注意的是，关于 SPLL-U 亚型中 BRAF 突变 (V600E) 和细胞周期蛋白 D3 表达的信息有限。因此，我们对BRAF突变（V600E）进行了病理分析，并表征了SPLL-U的病理特征。我们回顾了 12 例 SPLL-U 病例的病理结果。考虑的 12 例包括 2 例 HCL-v、6 例 SPLL-U-NS 和 4 例未确定的病例。 3例检测到BRAF突变（V600E），均为SPLL-U-NS。与缺乏BRAF突变的病例相比，具有BRAF突变(V600E)的病例具有增加的CD103表达水平和降低的细胞周期蛋白D3和细胞周期蛋白D1表达。这些发现表明 BRAF 突变可能在 SPLL-U 中发挥重要作用。因此，应该通过对大量 SPLL-U 患者进行基因组或转录分析来评估 BRAF 突变的重要性。
Primary splenic low‐grade B‐cell lymphoma of the red pulp comprises hairy cell leukemia (HCL) and splenic B‐cell lymphoma/leukemia, unclassifiable (SPLL‐U). SPLL‐U is a rare disease that includes subtypes of a hairy cell leukemia‐variant (HCL‐v), splenic diffuse red pulp small B‐cell lymphoma (SDRPL) and other types that are known as narrow sense SPLL‐U (SPLL‐U‐NS). Notably, limited information is available regarding theBRAFmutation (V600E) and cyclin D3 expression in subtypes of SPLL‐U. Therefore, we performed a pathological analysis of theBRAFmutation (V600E) and characterized pathological features of SPLL‐U. We reviewed the pathological findings of 12 SPLL‐U cases. The 12 cases considered included two cases of HCL‐v, six cases of SPLL‐U‐NS and four undetermined cases. TheBRAFmutation (V600E) was detected in three cases, which were all SPLL‐U‐NS. Cases with theBRAFmutation (V600E) have increased levels of CD103 expression and decreased cyclin D3 and cyclin D1 expression compared with cases that lacked theBRAFmutation. These findings suggest that theBRAFmutation might play a significant role in SPLL‐U. Therefore, the significance of theBRAFmutation should be evaluated via genomic or transcriptional analyses of a large cohort of SPLL‐U patients.